A comprehensive view of Diabetes. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Sustainability & Social Responsibility Market Intelligence Service.
INTERNATIONAL PATENT: ELI LILLY AND COMPANY FILES APPLICATION FOR "PEPTIDES FOR INCRETIN SYNTHESIS"
Published:
April 17, 2024
by U.S. Fed News
|
GlobalData predicts GLP-1 drugs will redefine big pharma sales; Eli Lilly's diabetes drug, Mounjaro, is forecasted to generate US$34.0B by 2029, surpassing the entire 2023 portfolio of Lilly, with the Alzheimer's drug donanemab adding another US$5.0B
Published:
April 17, 2024
by FiercePharma
|
Abbott reports Q1 organic sales growth, excluding COVID-19 related sales, of 10.8%; medical device and established pharmaceutical sales grew 14% during the quarter
Published:
April 17, 2024
by FierceBiotech
|
Three US Senators to question Novo Nordisk over the discontinuation of Levemir, a long-acting insulin, just before a significant price cut was due to take effect; over seven million patients in the US rely on insulin
Published:
April 17, 2024
by ForeignAffairs.co.nz
|
Eli Lilly and Company Submits Patent Application for GIPR-Agonist Compounds
Published:
April 17, 2024
by Pharmaceutical Patent News
|
Ask us about our Sustainability & Social Responsibility market view